Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma

World Journal of Hepatology

Volumn 6, Issue 11, 2014, Pages 818-824

  El Garem, Hassan ^a   Ammer, Ayman ^a   Shehab, Hany ^a   Shaker, Olfat ^a   Anwer, Mohammed ^a   El Akel, Wafaa ^a   Omar, Heba ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Hepatocellular carcinoma; MiRNA; Serum

Indexed keywords

EID: 84912041591     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i11.818     Document Type: Article

References (26)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 Suppl 8: S4-S66 [PMID: 11602373 DOI: 10.1016/S0959-8049(01)00267-2]
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-S78 [PMID: 12394209 DOI: 10.1097/00004836-200211002-000028]
3. Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I, Rodrigo L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520-527 [PMID: 12601348 DOI: 10.1053/jhep.2003.50093]
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
5. El-Attar IA. Cancer databases in the Arab world. Ethn Dis 2005; 15: S1-3-S1-4 [PMID: 15787030]
6. El-Nady GM, Ling R, Harrison TJ. Gene expression in HCVassociated hepatocellular carcinoma--upregulation of a gene encoding a protein related to the ubiquitin-conjugating enzyme. Liver Int 2003; 23: 329-337 [PMID: 14708893 DOI: 10.1034/j.1478-3231.2003.00862.x]
7. Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K, Pantalena M, Realdi G, Corrocher R, Schalm SW. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol 1998; 93: 896-900 [PMID: 9647014 DOI: 10.1111/j.1572-0241.1998.00272.x]
8. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118 [PMID: 19362088 DOI: 10.1053/j.gastro.2009.04.005]
9. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, Takenami K, Yamamoto M, Nakano M. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000; 88: 544-549 [PMID: 10649245 DOI: 10.1002/(SICI)1097-0142(20000201)88]
10. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004; 127: S113-S119 [PMID: 15508074 DOI: 10.1053/j.gastro.2004.09.024]
11. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175-205 [PMID: 17506695 DOI: 10.1146/annurev. cellbio.23.090506.123406]
12. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1]
13. Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, Lee CS, Wei TC. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404-1409 [PMID: 6201411]
14. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008; 2: 17-30 [PMID: 19669276 DOI: 10.1007/s12072-007-9038-x]
15. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J, Sauerbruch T, Dienes HP, Odenthal M. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 2013; 58: 234-239 [PMID: 23085648 DOI: 10.1016/j.jhep.2012.10.015]
16. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-142 [PMID: 21229610 DOI: 10.1002/mc.20712]
17. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47: 1223-1232 [PMID: 18307259 DOI: 10.1002/hep.22158]
18. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658 [PMID: 17681183 DOI: 10.1053/j.gastro.2007.05.022]
19. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P, Lee CG. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283: 13205-13215 [PMID: 18319255 DOI: 10.1074/jbc. M707629200]
20. Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, Li W, Bi J, Zhang LJ, Fu Q, Zeng WT, Cao LQ, Tan HX, Su Q. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 2009; 39: 786-794 [PMID: 19473441 DOI: 10.1111/j.1872-034X.2009.00502.x]
21. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173: 856-864 [PMID: 18688024 DOI: 10.2353/ajpath.2008.080096]
22. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47: 1955-1963 [PMID: 18433021 DOI: 10.1002/hep.22256]
23. Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, Waidmann O. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013; 49: 3442-3449 [PMID: 23810247 DOI: 10.1016/j.ejca.2013.06.002]
24. Zekri A, Youssef AS, Ahmed O. Serum MicroRNAs as differential markers and a molecular therapeutic target for HCV associated liver disease. AASLD 2013; poster
25. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56: 1371-1383 [PMID: 22314424 DOI: 10.1016/j.jhep.2011.11.026]
26. Rong M, Chen G, Dang Y. Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer 2013; 13: 21 [PMID: 23320393 DOI: 10.1186/1471-2407-13-21]